- Home
- GENC vs CHRS Comparison
GENC vs CHRS Comparison
Compare GENC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENC | CHRS |
|---|---|---|
| Founded | N/A | 2010 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 186.0M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GENC | CHRS |
|---|---|---|
| Price | $15.14 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $16.00 | $5.51 |
| AVG Volume (30 Days) | 25.3K | ★ 3.6M |
| Earning Date | 05-17-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.08 | ★ 109.88 |
| EPS | 0.23 | ★ 1.77 |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $125,306.93 | N/A |
| Revenue Next Year | $3.54 | $79.63 |
| P/E Ratio | $66.43 | ★ $0.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.80 | $0.72 |
| 52 Week High | $17.40 | $2.62 |
Technical Indicators
Market Signals| Indicator | GENC | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 39.67 |
| Support Level | $14.94 | $1.60 |
| Resistance Level | $16.00 | $2.20 |
| Average True Range (ATR) | 0.68 | 0.15 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 68.84 | 2.38 |
Price Performance
Historical ComparisonAbout GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.